Efficacy of antiandrogens in androgen receptor-positive triple-negative metastatic breast cancer: Real-life data
| Title: | Efficacy of antiandrogens in androgen receptor-positive triple-negative metastatic breast cancer: Real-life data |
|---|---|
| Authors: | Yasmine Rhanine; Hervé Bonnefoi; Anthony Goncalves; Marc Debled; Sylvestre Le Moulec; Nathalie Bonichon; Gaetan Macgrogan; Monica Arnedos; Bénédicte Dubroca-Dehez; Thomas Grellety |
| Source: | Breast, Vol 73, Iss , Pp 103667- (2024) |
| Publisher Information: | Elsevier |
| Publication Year: | 2024 |
| Collection: | Directory of Open Access Journals: DOAJ Articles |
| Subject Terms: | Androgen receptor-positive triple-negative breast cancer; Antiandrogens; Real-life data; Androgen receptor; Biomarker; Clinical benefit rate; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282 |
| Description: | Antiandrogens (AA) have been tested in clinical trials in androgen receptor (AR) + triple-negative breast cancer (TNBC). We aim to assess the clinical benefit rate (CBR) of AA in real life.The primary end-point was CBR at 6 months. Twenty-four patients were assessable and received: abiraterone acetate (62 %), enzalutamide (8 %) and bicalutamide (30 %). CBR at 6 months was 29 % (7/24) with 2 CR, 3 PR and 2 SD. Four patients had a clinical benefit >12 months. Real-life efficacy of AA use in metastatic AR + TNBC are in line with data from published trials. |
| Document Type: | article in journal/newspaper |
| Language: | English |
| Relation: | http://www.sciencedirect.com/science/article/pii/S0960977623007932; https://doaj.org/toc/1532-3080; https://doaj.org/article/344b27159eb14ac881aa9320bdf6aea4 |
| DOI: | 10.1016/j.breast.2023.103667 |
| Availability: | https://doi.org/10.1016/j.breast.2023.103667; https://doaj.org/article/344b27159eb14ac881aa9320bdf6aea4 |
| Accession Number: | edsbas.B6EBFFAC |
| Database: | BASE |